Skip to content
Screener

Biogen BIIB Collaboration profit sharing/(loss reimbursement)

Collaboration profit sharing/(loss reimbursement) at other companies

Delta Air Lines logo
Delta Air LinesDAL
-$13.25M-983%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$7.17M+72.1%
APi Group logo
APi GroupAPG
$11M+22.2%
Cass Information Systems logo
Cass Information SystemsCASS
$1.96M+23.8%
Cass Information Systems logo
Cass Information SystemsCASS
$1.96M+23.8%
NACCO Industries logo
NACCO IndustriesNC
$8.32M

Other financials

Income statement

See full
Revenue$2.7B+3.4%
Gross profit$2.0B-4.0%
Operating income$610.7M
Net income$97.5M-84.6%
EPS (diluted)$0.66-84.8%

Balance sheet

See full
Cash & equivalents$1.3B-53.4%
Total debt$7.6B+14.6%
Total equity$18.8B+6.9%
Total assets$32.1B+13.3%

Cash flow

See full
Operating cash flow$448.9M+179%
CapEx$40.9M+53.8%
Free cash flow$408.0M+204%

Valuation

See full
Market cap$30.48B+60.7%
Enterprise value$36.75B+61.2%
P/E34.5×+22.1×
P/S+1.1×

Profitability

See full
Gross margin74%-1.4pp
Operating margin22.9%
Net margin8.8%-6.5pp
FCF margin26.9%+7.1pp

Returns & leverage

See full
Return on equity4.8%-4.3pp
Debt / equity0.4×0.0×
Current ratio1.9×-0.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept biib:CollaborationProfitLossSharing.

The source filing: Biogen’s 10-K, filed February 6, 2026.

Filed
Feb 6, 2026, 7:36 AM EST
Fiscal year
FY2025
Accession
0000875045-26-000013

| --- | --- | --- | --- | | Revenue: | | | | | Acquired in-process research and development, upfront and milestone expense | 471.8 | 61.5 | 16.6 | | Selling, general and administrative | 2,433.6 | 2,403.7 | 2,549.7 | | Amortization and impairment of acquired intangible assets | 515.0 | 446.7 | 240.6 | | Collaboration profit sharing/(loss reimbursement) | 290.2 | 254.4 | 218.8 | | (Gain) loss on fair value remeasurement of contingent consideration | 33.6 | 27.7 | — | | Impairment of ROU asset | 52.9 | — | — | | Restructuring charges | 48.6 | 30.2 | 218.8 | | Gain on sale of priority review voucher, net | — | (88.6) | — |

ITEM 16. FORM 10-K SUMMARY

FAQ

What is Biogen's collaboration profit sharing/(loss reimbursement)?
Biogen (BIIB) reported collaboration profit sharing/(loss reimbursement) of $72.55M in Q4 2025.
How has Biogen's collaboration profit sharing/(loss reimbursement) changed year-over-year?
Biogen's collaboration profit sharing/(loss reimbursement) increased by 14.1% year-over-year, from $63.6M to $72.55M.
What is the long-term trend for Biogen's collaboration profit sharing/(loss reimbursement)?
Over 4 years (2021 to 2025), Biogen's collaboration profit sharing/(loss reimbursement) has grown at a 152.0% compound annual growth rate (CAGR), from $7.2M to $290.2M.
What does collaboration profit sharing/(loss reimbursement) mean?
The net impact of profit-sharing arrangements or loss reimbursements with strategic partners. This reflects the financial outcome of joint ventures or co-promotion agreements.

Ask your AI about Biogen's collaboration profit sharing/(loss reimbursement).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude